Call us + 65 2324-1623

Opening Hours Mon-Sat: 9:00 AM - 5:00 PM

Address 20 Eng Hoon Street, Singapore

MCF IVF Fertility How Age Shapes Fertility Testing and Timelines

How Age Shapes Fertility Testing and Timelines

Age is one of the strongest influences on fertility because it affects both the number of eggs remaining and their likelihood of producing a healthy pregnancy. Fertility testing can identify relevant factors, but it cannot precisely predict whether or when an individual will conceive. The American Society for Reproductive Medicine (ASRM) recommends evaluation after 12 months of trying for people under 35, after six months at 35 or older, and sooner when age is over 40 or a known risk factor is present. Understanding what tests measure, how results change with age, and when to seek care can help people make informed decisions without treating a test result as a verdict.

How age shapes fertility testing and timelines

Fertility refers to the capacity to achieve a pregnancy, while fertility testing is a clinical assessment of factors that may affect conception. Age matters differently for people who produce eggs and those who produce sperm. For people with ovaries, age-related changes in egg quantity and quality become more consequential through the 30s and especially after 35. For people who produce sperm, age-related changes tend to be more gradual, though age and health can still affect reproductive outcomes.

The Centers for Disease Control and Prevention (CDC) reports that about one in five married women ages 15–49 who have never given birth are unable to become pregnant after one year of trying. That population-level measure does not predict an individual’s prospects, but it highlights why timely evaluation matters. Age can influence both when testing should begin and how quickly clinicians may discuss treatment options.

Age-related fertility and testing timelines

ASRM defines infertility as a disease, condition, or status characterized by the inability to establish a successful pregnancy after regular, unprotected sexual intercourse—or, for people using donor sperm, therapeutic donor insemination—over a specified period. In its committee opinion on fertility evaluation, ASRM advises beginning an evaluation after 12 months of trying for women under 35, after six months for women 35 and older, and more immediately for women over 40. Evaluation should begin without waiting when there is a known concern such as absent or irregular periods, suspected endometriosis, prior pelvic infection, or a possible sperm-related problem.

These are clinical guideposts, not deadlines that require someone to wait if they are worried. Fertility testing is not a single test: it may include menstrual and medical history, assessment of ovulation, imaging of the uterus and fallopian tubes, and semen analysis. Which tests are appropriate depends on age, symptoms, reproductive history, and how long pregnancy has been attempted.

Egg quantity and ovarian reserve

Ovarian reserve describes the remaining supply of eggs and is commonly assessed with blood tests for anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH), alongside an ultrasound count of antral follicles. The American College of Obstetricians and Gynecologists (ACOG) explains that AMH is produced by small ovarian follicles and can help estimate ovarian response to fertility medication. These measures are useful in treatment planning, particularly for estimating likely response during in vitro fertilization (IVF), but they do not directly measure egg quality or reliably predict natural conception in someone without infertility.

Age and ovarian reserve are related, but they are not interchangeable. A person of the same age can have a different test result from another person, and a reassuring result cannot cancel age-related changes in egg quality. ASRM cautions against using ovarian reserve tests as fertility screening for people who have not been diagnosed with infertility. Results should be interpreted with a clinician rather than used alone to decide whether pregnancy is possible.

Egg quality, pregnancy, and age

Egg quality refers, in clinical discussions, to an egg’s ability to support fertilization and embryo development; it is not measured by a routine blood test. The proportion of eggs with chromosome abnormalities rises with age, which helps explain why conception may take longer and miscarriage risk increases as people age. ACOG notes that fertility begins to decline gradually around age 30, with a more rapid decline after the mid-30s. These are broad population patterns, not a prediction of an individual’s outcome.

The CDC’s 2022 National Summary Report on assisted reproductive technology (ART) shows that outcomes using a patient’s own eggs vary by age and treatment stage. Such figures describe groups treated at U.S. clinics; they are not equivalent to the chance of conceiving naturally, and they do not account for every personal factor. When reviewing statistics, check whether a figure refers to a cycle started, an embryo transfer, or a live birth, and whether donor eggs are included.

Ovulation, menstrual history, and reproductive conditions

Ovulation is the release of an egg from an ovary. Menstrual cycles that are consistently very irregular or absent can indicate that ovulation is infrequent or not occurring, so clinicians may investigate sooner rather than waiting for the standard time threshold. Depending on the history, evaluation may consider polycystic ovary syndrome (PCOS), thyroid disorders, elevated prolactin, endometriosis, or other conditions. A cycle history is often an important starting point, but regular periods do not rule out every fertility issue.

For people with a uterus and fallopian tubes, testing may include transvaginal ultrasound and a study such as hysterosalpingography, which uses contrast imaging to assess whether the tubes appear open and to examine the uterine cavity. These tests address different questions from ovarian-reserve testing. The clinical aim is to identify treatable factors and choose the right next step, not to generate a single all-purpose fertility score.

Sperm testing and age

Semen analysis assesses characteristics such as sperm concentration, movement, and shape. ASRM recommends evaluating both partners, when applicable, as part of an infertility assessment rather than focusing only on the person who may become pregnant. Sperm-related factors can contribute to difficulty conceiving at any age, so testing may be appropriate early in the process when there is a relevant medical history or concern.

Sperm production continues throughout life, but paternal age can be associated with changes in semen parameters and a gradual increase in some reproductive risks. The evidence and the size of these changes differ from those for age-related egg decline. A clinician should interpret age alongside medical history, medication use, lifestyle, and the test results themselves.

How testing results guide next steps

Fertility tests are most useful when they answer a specific clinical question. A clinician may use the findings to identify a possible cause, decide whether additional investigation is needed, estimate how the ovaries may respond to stimulation, or discuss options such as timed intercourse, insemination, or IVF. No test can guarantee success, and a normal result does not rule out unexplained infertility.

Age can make the timing of decisions especially important because some treatment options rely on a person’s own eggs, while others may involve donor eggs or embryos. For example, a person aged 37 who has been trying for six months may reasonably seek evaluation rather than waiting another six months, even if cycles are regular. Conversely, a low AMH result in someone who has not been trying to conceive does not, by itself, establish infertility or mean pregnancy is impossible.

A useful way to compare treatment statistics is to ask the clinic for outcomes that match the relevant age group and treatment pathway. For IVF, clarify whether reported success means pregnancy or live birth, whether it is calculated per cycle or per embryo transfer, and whether the numbers use the patient’s eggs or donor eggs. These distinctions make statistics more meaningful and reduce the risk of comparing unlike figures.

When to seek a fertility evaluation

  • Under age 35: Consider evaluation after 12 months of regular, unprotected intercourse without pregnancy.
  • Age 35–40: Consider evaluation after six months; consult sooner if there are known concerns.
  • Over age 40: Seek medical advice promptly when planning pregnancy or experiencing difficulty conceiving.
  • At any age: Seek earlier assessment for absent or highly irregular periods, suspected endometriosis, prior pelvic infection or reproductive surgery, recurrent pregnancy loss, or a known sperm-related concern.

A primary-care clinician or obstetrician-gynecologist can begin an evaluation and refer to a reproductive endocrinologist when appropriate. People who are considering fertility preservation, donor conception, or pregnancy after cancer treatment may benefit from discussing options before trying to conceive, since timelines and testing needs differ.

Conclusion: Use age as a guide, not a diagnosis

Age shapes fertility testing timelines because egg quantity, egg quality, and reproductive outcomes change over time, while sperm-related effects generally follow a different and more gradual pattern. Ovarian-reserve tests, ovulation assessment, imaging, and semen analysis each provide specific information; none can independently predict an individual’s ability to conceive. Following ASRM’s recommended evaluation windows—and seeking care sooner when risk factors exist—can help people understand their options and avoid unnecessary delays. For personalized guidance, discuss age, health history, and testing results with a qualified clinician.

Sources: American Society for Reproductive Medicine, Fertility evaluation of infertile women: a committee opinion, 2021, https://www.asrm.org/practice-guidance/practice-committee-documents/fertility-evaluation-of-infertile-women-a-committee-opinion-2021/; American Society for Reproductive Medicine, Testing and interpreting measures of ovarian reserve: a committee opinion, 2020, https://www.asrm.org/practice-guidance/practice-committee-documents/testing-and-interpreting-measures-of-ovarian-reserve-a-committee-opinion-2020/; American College of Obstetricians and Gynecologists, Infertility Workup for the Women’s Health Specialist, https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/06/infertility-workup-for-the-womens-health-specialist; Centers for Disease Control and Prevention, Infertility, https://www.cdc.gov/reproductive-health/infertility/; Centers for Disease Control and Prevention, 2022 Assisted Reproductive Technology Fertility Clinic and National Summary Report, https://www.cdc.gov/art/reports/2022/index.html